P3.01-12 EGFR Mutation and Targeted Therapies: Difficulties and Disparities in Access to NSCLC Treatment in Brazil

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1572
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P23 Stage IIIb NSCLC and Curative Intention Treatment: Difficulties and Disparities in Brazil

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-33 EGFR Mutation in Patients With NSCLC and Its Relationship Between Survival and Clinicopathological Features: An Update Analysis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC

Neoplasma
Cancer Research
2013English

Expanding Targeted Therapies for NSCLC

Cancer Discovery
Oncology
2014English

P3.01-80 Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients With NSCLC Harboring EGFR Mutations.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-16 Low Dose Apatinib Combined With EGFR-TKI in Treating Advanced NSCLC After First-Generation EGFR-TKIs Treatment Failure

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-75 RELAY+, an Exploratory Study of Gefitinib With Ramucirumab in Untreated Patients With EGFR Mutation-Positive Metastatic NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-20 Advanced NSCLC Treatment and Outcomes After Nivolumab

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Lung Cancer Management
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy